Home Cart Sign in  
Chemical Structure| 1628606-05-2 Chemical Structure| 1628606-05-2

Structure of Vimseltinib
CAS No.: 1628606-05-2

Chemical Structure| 1628606-05-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Vimseltinib (DCC-3014) is a highly selective dual inhibitor of c-FMS (CSF-1R) and c-Kit (with IC50 values of <0.01 μM and 0.1–1 μM, respectively). It reduces tumor-associated macrophages (TAMs) by inhibiting CSF-1R, thereby blocking the formation of a pro-tumor microenvironment. It has entered Phase III clinical trials for the treatment of tenosynovial giant cell tumor (TGCT).

Synonyms: DCC-3014

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Vimseltinib

CAS No. :1628606-05-2
Formula : C23H25N7O2
M.W : 431.49
SMILES Code : O=C1C(C2=CC=C(OC3=CC=NC(C4=CN(C)N=C4)=C3)C(C)=N2)=CN=C(N1C)NC(C)C
Synonyms :
DCC-3014
MDL No. :MFCD32858282
InChI Key :TVGAHWWPABTBCX-UHFFFAOYSA-N
Pubchem ID :86267612

Safety of Vimseltinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Related Pathways of Vimseltinib

RTK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06619561 Chronic Graft-Versus-Host Dise... More >>ase (cGVHD) Less << PHASE2 RECRUITING 2025-10-29 City of Hope National Medical ... More >>Center, Duarte, California, 91010, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States Less <<
NCT03069469 Advanced Malignant Neoplasm|Pi... More >>gmented Villonodular Synovitis|Giant Cell Tumor of Tendon Sheath|Tenosynovial Giant Cell Tumor|Tenosynovial Giant Cell Tumor, Diffuse Less << PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-08-28 Stanford Cancer Institute, Pal... More >>o Alto, California, 94304, United States|University of Colorado - Denver, Denver, Colorado, 80204, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|University of Miami, Miami, Florida, 33136, United States|Dana Farber, Boston, Massachusetts, 02215, United States|MSKCC, New York, New York, 10065, United States|OHSU, Portland, Oregon, 97239, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Peter MacCallum Cancer Centre, Melbourne, Australia|McGill University Health Centre, Montréal, Quebec, Canada|Princess Margaret Cancer Center, Toronto, Canada|Centre Leon Berard, Lyon, France|Gustave Roussy Cancer Campus Grand Paris, Paris, France|IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy|Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy|Istituto Nazionale dei Tumori, Milan, Italy|Regina Elena National Cancer Institute, Rome, Italy|Leiden University Medical Center, Leiden, Netherlands|M. Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Sevilla, Spain|University College Hospital, London, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.59mL

2.32mL

1.16mL

23.18mL

4.64mL

2.32mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories